![https://www.trademarkia.com 2019-03-28 daily https://trademark.trademarkia.com/glave-gunner-85893110.html https://mark.trademarkia.com/logo-images/ro8o-corp/glave-gunner-85893110.jpg Pencils, pens (excluding quill pens), crayons, pen points, chalk ... https://www.trademarkia.com 2019-03-28 daily https://trademark.trademarkia.com/glave-gunner-85893110.html https://mark.trademarkia.com/logo-images/ro8o-corp/glave-gunner-85893110.jpg Pencils, pens (excluding quill pens), crayons, pen points, chalk ...](https://mark.trademarkia.com/logo-images/spireops-inc/spireops-edv-85893106.jpg)
https://www.trademarkia.com 2019-03-28 daily https://trademark.trademarkia.com/glave-gunner-85893110.html https://mark.trademarkia.com/logo-images/ro8o-corp/glave-gunner-85893110.jpg Pencils, pens (excluding quill pens), crayons, pen points, chalk ...
![BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool](https://mms.businesswire.com/media/20170801006281/en/604221/4/AML_infographic_8117---FINAL.jpg)
BusinessWire - Celgene Corporation (CG3) FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation | ResearchPool
![BusinessWire - MACOM Technology Solutions Holdings Inc. (MTSI) MACOM and STMicroelectronics to Bring GaN on Silicon to Mainstream RF Markets and Applications | ResearchPool BusinessWire - MACOM Technology Solutions Holdings Inc. (MTSI) MACOM and STMicroelectronics to Bring GaN on Silicon to Mainstream RF Markets and Applications | ResearchPool](https://mms.businesswire.com/media/20180206006289/en/639352/4/ST_Macom_co_branded_logo_vert_webready.jpg)